Inaccurate recognition of own comorbidities is associated with poor prognosis in elderly patients with heart failure

Daichi Maeda1,2, Yuya Matsue1,3*, Nobuyuki Kagiyama4,5,6, Kentaro Jujo7, Kazuya Saito8, Kentaro Kamiya9, Hiroshi Saito1,10, Yuki Ogashara11, Emi Maekawa12, Masaaki Konishi13, Takeshi Kita14,15, Kentaro Iwata15, Hiroshi Wada16, Masaru Hiki1, Taishi Dotare1, Tsutomu Sunayama1, Takatoshi Kasai1,3, Hirofumi Nagamatsu17, Tetsuya Ozawa18, Katsuya Izawa19, Shuhei Yamamoto20, Naoki Aizawa21, Ryusuke Yonezawa22, Kazuhiro Oka23, Shin-ichi Momomura24 and Tohru Minamino1,25

1Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan; 2Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; 3Department of Cardiology, The Sakakibara Heart Institute of Okayama, Okayama, Japan; 4Department of Digital Health and Telemedicine R&D, Juntendo University, Tokyo, Japan; 5Department of Cardiovascular Biology and Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan; 6Department of Cardiology, Juntendo University Heart Center Hospital, Tokyo, Japan; 7Department of Rehabilitation, The Sakakibara Heart Institute of Okayama, Okayama, Japan; 8Department of Rehabilitation, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan; 9Department of Rehabilitation, Kameda Medical Center, Kamogawa, Japan; 10Department of Nursing, The Sakakibara Heart Institute of Okayama, Okayama, Japan; 11Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan; 12Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan; 13Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan; 14Department of Rehabilitation, Kobe City Medical Center General Hospital, Kobe, Japan; 15Department of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan; 16Department of Cardiology, Tokai University School of Medicine, Isehara, Japan; 17Department of Rehabilitation, Odawara Municipal Hospital, Odawara, Japan; 18Department of Rehabilitation, Kasukabe Chuo General Hospital, Kasukabe, Japan; 19Department of Rehabilitation, Shinshu University Hospital, Matsumoto, Japan; 20Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus, Okinawa, Japan; 21Rehabilitation Center, Kitasato University Medical Center, Klamata, Japan; 22Department of Rehabilitation, Saitama Citizens Medical Center, Saitama, Japan; 23Department of Rehabilitation, Saitama Citizens Medical Center, Saitama, Japan; and 24Japan Agency for Medical Research and Development-Care Research for Evolutionary Medical Science and Technology (AMED-CREST), Japan Agency for Medical Research and Development, Tokyo, Japan

Abstract

Aims A patient’s understanding of his or her own comorbidities is part of the recommended patient education for those with heart failure. The accuracy of patients’ understanding of their comorbidities and its prognostic impact have not been reported.

Methods and results Patients hospitalized for heart failure (n = 1234) aged ≥65 years (mean age: 80.1 ± 7.7 years; 531 females) completed a questionnaire regarding their diagnoses of diabetes, malignancy, stroke, hypertension, chronic obstructive pulmonary disease (COPD), and coronary artery disease (CAD). The patients were categorized into three groups based on the number of agreements between self-reported comorbidities and provider-reported comorbidities: low (1–2, n = 19); fair (3–4, n = 376); and high (5–6, n = 839) agreement groups. The primary outcome was a composite of all-cause mortality or heart failure rehospitalization at 1 year. The low agreement group had more comorbidities and a higher prevalence of a history of heart failure. The agreement was good for diabetes (κ = 0.73), moderate for malignancy (κ = 0.56) and stroke (κ = 0.50), and poor-to-fair for hypertension (κ = 0.33), COPD (κ = 0.25), and CAD (κ = 0.30). The fair and low agreement groups had poorer outcomes than the good agreement group [fair agreement group: hazard ratio (HR): 1.25; 95% confidence interval (CI): 1.01–1.56; P = 0.041; low agreement group: HR: 2.74: 95% CI: 1.40–5.35; P = 0.003].

Conclusions The ability to recognize their own comorbidities among older patients with heart failure was low. Patients with less accurate recognition of their comorbidities may be at higher risk for a composite of all-cause mortality or heart failure rehospitalization.

Keywords Acute heart failure; Elderly; Questionnaire; Comorbidities; Agreement; Prognosis

Received: 29 June 2021; Revised: 30 November 2021; Accepted: 14 January 2022

Correspondence to: Yuya Matsue, MD, PhD, Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; Tel: +81-3-3813-3111; Fax: +81-3-5689-0627, Email: yuya8850@gmail.com

Trial registration: University Hospital Information Network (UMIN-CTR: UMIN000023929)
Introduction

Heart failure is one of the leading global causes of public health concerns and mortality. As heart failure is strongly associated with older age, cardiac and non-cardiac comorbidities are prevalent in patients with heart failure.1–3 Recent studies have reported that the number of comorbidities in patients with heart failure increases over time and that the presence of more comorbidities is associated with higher mortality.4

Patient education is key to prevent disease progression and provide better disease management. The American College of Cardiology Foundation and the American Heart Association guidelines and European Society of Cardiology guidelines for heart failure recommend providing adequate patient education that allows the patient to better understand heart failure as a disease and perform self-care, including symptom monitoring.5,6 The understanding and recognition of one’s own comorbidities is an essential and fundamental aspect of patient education.7 Studies on the general population,1–3,8,9 patients with cancer,10–12 and patients with chronic kidney disease13,14 have reported that patients do not necessarily recognize their own comorbid conditions that are recorded in their medical records and that the agreement between self-reported and provider-reported comorbidities is generally poor. The accuracy of self-reported comorbidities among patients with heart failure has not been reported. A poor understanding or recognition of comorbid conditions may be associated with a poor prognosis, based on previous studies that have suggested that better self-care behaviour reduces heart failure hospitalizations and the mortality rate in patients with heart failure;5,6 however, study has investigated the association between the patient’s awareness of his or her own comorbidities and the prognosis in any patient population. Therefore, in this study, we investigated the agreement between self-reported and provider-reported comorbidities, the predictive factors for the disagreement between the reported comorbidities, and the association between the agreement and prognosis in older patients with heart failure.

Methods

Study design

This study is a post hoc analysis of data from the FRAGILE-HF study, which was a prospective, multicentre, observational study that evaluated the prevalence and prognostic value of physical, social, and cognitive frailty in older patients hospitalized for heart failure. The detailed study design and results of the FRAGILE-HF study have been published elsewhere.17–19 In brief, 1332 patients aged ≥65 years hospitalized for heart failure, who could walk alone at discharge, were enrolled from 15 hospitals in Japan between September 2016 and March 2018. The diagnosis of heart failure was based on the Framingham criteria.20 Patients with a previous heart transplantation or left ventricular assist device implantation, chronic peritoneal dialysis or haemodialysis, or acute myocarditis were excluded.

This study was conducted according to the principles of the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research involving Human Subjects. All patients were notified regarding their participation in our study and were provided the opportunity to opt out. As this was an observational study without invasive interventions, written informed consent was not required, as per the Ethical Guidelines for Medical and Health Research Involving Human Subjects, issued by the Japanese Ministry of Health, Labor, and Welfare. The study protocol was approved by the Sakakibara Heart Institution of Okayama Research Ethics Committee. The study information such as aims, inclusion and exclusion criteria, primary endpoint, and participating hospitals have been published in the publicly available University Hospital Information Network (UMIN-CTR, unique identifier: UMIN000023929).

Data collection

Physical examination, echocardiography, blood tests, and oral medication data were collected when the patients were in a clinically compensated state, prior to discharge. A history of heart failure was defined as having been diagnosed with heart failure before index hospitalization. Cognitive function was evaluated using the Mini-Cog test, on which scores ≤ 2 points were defined as cognitive dysfunction.21

In the FRAGILE-HF study, the investigators reported the presence or absence of six comorbidities (hypertension, diabetes, cancer, chronic lung disease, coronary artery disease, and stroke) for all patients on a case report form (CRF). These six comorbidities are included in the Frail Scale questionnaire22,23 as the following question: ‘Did a doctor ever tell you that you have [disease]?’.22,23 All patients in the FRAGILE-HF study completed the Frail Scale questionnaire.

Outcomes

One-year outcomes were prospectively collected in the FRAGILE-HF study. The predetermined primary outcome included all-cause mortality and heart failure rehospitalization, which was defined according to the American College of Cardiology/American Heart Association Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials.24 Most study patients were followed up as outpatients.
in clinics at least every 3 months and as medically needed. For patients who did not attend outpatient follow-up visits, clinical outcomes were collected via telephone interviews, medical records from other medical institutions, or interviews with the patients’ families.

**Statistical analysis**

Variables with normal distribution are presented as mean and standard deviation, and those with non-normal distribution are presented as median and interquartile range. Categorical variables are reported as numbers and percentages. Continuous data were compared using Student’s *t*-tests or Mann–Whitney *U* tests, and categorical data were compared using χ² or Fisher’s exact tests, as appropriate.

The agreement between the comorbidities reported by the patient and those included in the CRF was evaluated using Cohen’s Kappa (κ) coefficient. The classification of Landis and Koch was used to evaluate the agreement levels: poor-to-fair (κ < 0.40), moderate (0.40 < κ ≤ 0.60), substantial (0.60 < κ ≤ 0.80), and almost perfect (0.80 < κ ≤ 1.00). The sensitivity (correctly self-reported ‘Yes’/CRF ‘Yes’), specificity (correctly self-reported ‘No’/CRF ‘No’), positive predictive value (correctly self-reported ‘Yes’/all self-reported ‘Yes’), negative predictive value (correctly self-reported ‘No’/all self-reported ‘No’), false-positive (incorrectly self-reported ‘Yes’/CRF ‘No’), false-negative (incorrectly self-reported ‘No’/CRF ‘Yes’), and overall agreement (correctly self-reported ‘Yes’ and ‘No’/all answers) were calculated using the CRF-based presence or absence of comorbidities as a gold standard. False-positives were defined as over-reporting and false-negatives as under-reporting. The agreement score was defined as the number of comorbidities with agreement between the patient’s report and the CRF. The agreement score was calculated for each patient and used to determine how accurately the patients recognized their own comorbidities. The agreement score ranged from 0 to 6. The patients were divided into three groups according to the agreement score: low agreement group (agreement score, 1–2), fair agreement group (agreement score, 3–4), and high agreement group (agreement score, 5–6). Group differences were evaluated using one-way analysis of variance or the Kruskal–Wallis test for continuous variables, and χ² or Fisher’s exact test for dichotomous variables, as appropriate.

Univariate and multivariable logistic regression analyses were used to identify patient characteristics related to the agreement of each comorbidity. A Kaplan–Meier analysis with a log-rank test was used to compare the prognosis between groups stratified by the agreement score into the following four groups: complete agreement (patients with agreement score of 6), patients with more under-reporting, patients with more over-reporting, and patients with equal under-reporting and over-reporting. For example, patients who under-reported two comorbidities and over-reported one comorbidity were classified into the under-reporting group. Unadjusted and adjusted Cox proportional hazards analyses were performed to assess the association between clinical variables and prognosis. In adjusted Model 1, well-known prognostic factors for heart failure were adjusted for, including age, sex, body mass index, New York Heart Association class III or IV at discharge, current smoking status, systolic blood pressure, prior history of heart failure, hypertension, diabetes mellitus, atrial fibrillation, coronary artery disease, chronic obstructive pulmonary disease (COPD), estimated glomerular filtration rate, haemoglobin, serum albumin, serum sodium, log-transformed brain natriuretic peptide, left ventricular ejection fraction, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker prescriptions, beta-blocker prescriptions, and mineralocorticoid receptor antagonist prescriptions. In adjusted Model 2, the variables in Model 1 and the number of comorbidities and cognitive dysfunction were accounted for as these have also been reported to be risk factors for prognosis in patients with heart failure.

Multiple imputation was used for the missing covariate data to construct multivariable Cox regression models. Twenty datasets were created using a chained-equations procedure. Parameter estimates were obtained for each dataset and subsequently combined to produce an integrated result using the method described by Barnard and Rubin.

All analyses were performed using R software Version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria; ISBN: 3-900051-07-0, URL: http://www.R-project.org). Statistical significance was set at *P* < 0.05.

**Results**

Among the 1332 patients aged ≥65 years hospitalized for heart failure who were enrolled in the FRAGILE-HF study, 98 (7.4%) were excluded from this study due to missing data on the CRF or Frail Scale questionnaire. Therefore, the final analyses included 1234 patients, including 19 in the low agreement group, 376 in the fair agreement group, and 839 in the high agreement group. The patients’ baseline characteristics are shown in Table 1. There were no differences in sex, left ventricular ejection fraction, oral medications, or laboratory data between the groups. More patients in the low agreement group had histories of diabetes, COPD, stroke, and heart failure. The number of comorbidities and the prevalence of cognitive dysfunction were lower in the high agreement group than in the other groups. The agreements of each comorbidity are described in Table 2. The κ coefficient levels were poor-to-fair for hypertension (κ = 0.33), COPD (κ = 0.25), and coronary artery disease (κ = 0.30); moderate

DOI: 10.1002/ehf2.13824
for malignancy ($\kappa = 0.56$) and stroke ($\kappa = 0.50$); and substantial for diabetes mellitus ($\kappa = 0.73$). Overall, there was more under-reporting than over-reporting of all comorbidities except hypertension.

Older age was observed to be associated with lower levels of agreement for malignancy and coronary artery disease, and a longer history of heart failure was associated with a lower level of agreement for hypertension and coronary artery disease (Supporting Information, Table S1). Cognitive dysfunction was also related to a lower level of agreement for hypertension. For 4/6 comorbidities, a greater number of comorbidities was associated with lower levels of agreement.

Table 1 Patient characteristics

| Variable                      | Low agreement group | Fair agreement group | High agreement group | P-value |
|-------------------------------|---------------------|----------------------|----------------------|---------|
|                              | n = 19              | n = 376              | n = 839              |         |
| Age (years)                   | 81 [74, 86]         | 82 [76, 87]         | 80 [74, 85]         | <0.001  |
| Male sex, n (%)              | 13 (68.4)           | 221 (58.8)          | 469 (55.9)          | 0.39    |
| Living status, n (%)         |                     |                      |                      | 0.65    |
| Living with someone          | 16 (84.2)           | 276 (73.4)          | 638 (76.0)          |         |
| Living alone                 | 3 (15.8)            | 84 (22.3)           | 174 (20.7)          |         |
| Living in a nursery home     | 0 (0)               | 16 (4.3)            | 27 (3.2)            |         |
| Currently smoking, n (%)     | 2 (10.5)            | 28 (7.5)            | 87 (10.4)           | 0.27    |
| NYHA class III/IV, n (%)     | 4 (21.1)            | 48 (12.8)           | 121 (14.4)          | 0.50    |
| Body mass index (kg/m²)      | 20.5 (2.6)          | 21.4 (3.8)          | 21.4 (3.8)          | 0.60    |
| Systolic blood pressure (mmHg) | 112 (15)         | 113 (16)           | 114 (18)            | 0.46    |
| Diastolic blood pressure (mmHg) | 61 (9)             | 62 (11)            | 62 (11)             | 0.94    |
| Heart rate (b.p.m.)          | 71 (11)             | 71 (14)             | 71 (14)             | 0.78    |
| Left ventricular ejection fraction (%) | 47 (16)            | 46 (17)             | 46 (17)             | 0.95    |
| Atrial fibrillation, n (%)   | 14 (73.7)           | 174 (46.3)          | 355 (42.3)          | 0.014   |
| Coronary artery disease, n (%) | 7 (36.8)           | 165 (43.9)          | 263 (31.3)          | <0.001  |
| COPD, n (%)                  | 7 (36.8)            | 68 (18.1)           | 58 (6.9)            | <0.001  |
| Diabetes, n (%)              | 11 (57.9)           | 150 (39.9)          | 275 (32.8)          | 0.007   |
| Hypertension, n (%)          | 16 (84.2)           | 265 (70.5)          | 598 (71.3)          | 0.44    |
| Stroke, n (%)                | 3 (15.8)            | 68 (18.1)           | 110 (13.1)          | 0.066   |
| Number of comorbidities      | 2.7 (1.1)           | 2.1 (1.1)           | 1.6 (1.1)           | <0.001  |
| Cognitive dysfunction, n (%) | 8 (42.1)            | 163 (43.6)          | 287 (34.4)          | 0.008   |
| History of heart failure, n (%) |                  |                      |                      | <0.001  |
| None                         | 6 (31.6)            | 138 (36.7)          | 411 (49.0)          |         |
| Less than 1.5 years          | 2 (10.5)            | 75 (19.9)           | 114 (13.6)          |         |
| More than 1.5 years          | 11 (57.9)           | 163 (43.4)          | 313 (37.4)          |         |
| Prescription at discharge, n (%) |                  |                      |                      |         |
| Loop diuretics               | 13 (68.4)           | 220 (58.5)          | 455 (54.2)          | 0.20    |
| ACE-I/ARB                    | 13 (68.4)           | 257 (67.6)          | 568 (67.7)          | 0.99    |
| Beta-blocker                 | 15 (78.9)           | 276 (73.4)          | 608 (72.5)          | 0.79    |
| MRA                          | 3 (15.8)            | 26 (6.9)            | 74 (8.8)            | 0.27    |
| Laboratory data at discharge |                  |                      |                      |         |
| Haemoglobin (g/dL)           | 11.1 (1.2)          | 11.7 (1.9)          | 11.9 (2.1)          | 0.10    |
| Albumin (g/dL)               | 3.5 (0.3)           | 3.4 (0.5)           | 3.5 (0.5)           | 0.29    |
| Creatinine (mg/dL)           | 1.31 (0.63)         | 1.44 (0.94)         | 1.35 (0.78)         | 0.24    |
| Blood urea nitrogen (mg/dL)  | 23 [20, 28]         | 27 [21, 37]         | 26 [19, 35]         | 0.15    |
| Sodium (mEq/L)               | 138.8 (3.9)         | 138.9 (4.0)         | 139.0 (3.7)         | 0.88    |
| Potassium (mEq/L)            | 4.4 (0.5)           | 4.4 (0.5)           | 4.4 (0.5)           | 0.80    |
| BNP (pg/mL)                  | 297.4 [101.7, 402.5] | 282.7 [139.0, 493.7] | 264.0 [132.4, 491.1] | 0.71    |

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.

Variables are described as mean (standard deviation) or median [interquartile range].

Table 2 Agreement between self-reported and provider-reported comorbidities

| Comorbidity              | Kappa   | 95% CI  | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | False negative (%) | False positive (%) | Overall agreement (%) |
|--------------------------|---------|---------|-----------------|-----------------|---------|---------|---------------------|---------------------|-----------------------|
| Hypertension             | 0.33    | 0.27–0.38| 69.0            | 68.2            | 84.4    | 47.1    | 31.0                | 31.7                | 68.8                  |
| Diabetes                 | 0.73    | 0.69–0.77| 77.7            | 93.9            | 87.4    | 88.5    | 22.3                | 6.1                 | 88.1                  |
| Malignancy               | 0.56    | 0.50–0.63| 68.6            | 91.7            | 58.8    | 94.4    | 31.4                | 8.3                 | 88.3                  |
| COPD                     | 0.25    | 0.15–0.35| 32.6            | 92.1            | 33.1    | 91.9    | 67.4                | 7.9                 | 85.7                  |
| Coronary artery disease  | 0.30    | 0.25–0.36| 61.0            | 70.4            | 53.1    | 76.6    | 39.0                | 29.6                | 67.1                  |
| Stroke                   | 0.50    | 0.42–0.57| 63.6            | 90.9            | 51.5    | 94.3    | 36.4                | 9.1                 | 87.4                  |

CI, confidence interval; COPD, chronic obstructive pulmonary disease; NPV, negative predictive value; PPV, positive predictive value.
Among the 1234 study patients, 1210 (98.1%) were followed up until 1 year. The primary endpoint occurred in 402 patients (33.2%), including 10 patients (55.6%) in the low agreement group, 144 (39.3%) in the fair agreement group, and 248 (30.0%) in the high agreement group ($P < 0.001$, $P$ for trend = 0.002). Hospitalization for heart failure was observed in 202 (24.5%) patients in the high agreement group, 119 (32.7%) in the fair agreement group, and 8 (47.2%) in the low agreement group ($P = 0.003$, $P$ for trend < 0.001). All-cause mortality was observed in 88 (10.6%) patients in the high agreement group, 54 (14.8%) in the fair agreement group, and 3 (16.7%) in the low agreement group ($P = 0.108$, $P$ for trend = 0.036) (Figure 2). Lower agreement was associated with a higher incidence of the primary endpoint (Figure 2) (log-rank: $P < 0.001$). This association was retained even after adjustment for other factors related to the primary outcome, including cognitive dysfunction and number of comorbidities (Table 3). Patients who under-reported or over-reported their comorbidities were more likely to have a poor prognosis than those in the complete agreement group (Supporting Information, Figure S1). Furthermore, no difference in prognosis was observed between patients who under-reported, over-reported, or equally under-reported and over-reported their comorbidities in adjusted Model 2 (Supporting Information, Table S2).

**Discussion**

The agreement between self-reported and provider-reported comorbidities is low among older patients with heart failure. The low agreement rate is more due to under-reporting than over-reporting by the patients. Patients with lower agreement levels had a higher incidence of primary outcomes independent of other covariates, including the number of comorbidities.

This is the first study to report that the agreement between self-reported and provider-reported comorbidities among older hospitalized patients with heart failure is generally poor. Though a direct comparison was not performed, the agreements of hypertension, diabetes mellitus, COPD, and coronary artery disease were numerically lower in patients with heart failure compared with the general elderly population,\(^{1,3}\) patients with cancer,\(^ {10-12}\) and patients with chronic kidney disease,\(^ {13,14}\) which may be due to a variety of reasons. As the FRAGILE-HF study focused on older patients with heart failure, the patient population in this study included older patients, and age is a strong predictor of disagreement between patient reports and medical records regarding the presence or absence of comorbidities.\(^ {9,11,12,28}\) However, the cohorts evaluated in some previous studies were the same age or older than the patients included in this study.\(^ {1-3}\) Therefore, heart failure itself might have contributed to the poor agreement observed in this study. The presence of cognitive dysfunction, which is strongly associated with heart failure, might have also contributed to the higher levels of disagreement in our study. A previous meta-analysis reported that patients with heart failure had a 1.67 times higher risk of cognitive impairment than patients without heart failure.\(^ {29}\) Cognitive dysfunction is likely to be associated with disagreement due to memory disorders or a lack of recognition. While 38% of the patients in this study had cognitive dysfunction, previous studies have either included very few patients with cognitive dysfunction,\(^ {2}\) excluded patients with cognitive dysfunction,\(^ {3}\) or did not report the presence or absence of cognitive dysfunction.\(^ {1,8-14,28}\) The number of
comorbidities may also be associated with disagreement. Patients with heart failure often have a high number of comorbidities. A clinical study on 122,630 patients with chronic heart failure reported that 39% had at least five comorbidities and 4% had no comorbidities. An association between the number of comorbidities patients incorrectly recognize and the total number of comorbidities has been previously reported, which is consistent with the results of this study.

In this study, the agreement levels varied widely among the different comorbidities. One possible explanation for these results might be the clarity in the definition of the diseases. Although diabetes mellitus is explicitly defined based on the blood test results, the diagnosis of hypertension, COPD, and coronary artery disease is less than clear-cut. Blood pressure varies depending on the time or place (i.e. home or hospital), and there is insufficient awareness regarding hypertension. Similarly, the awareness rate of COPD is reportedly extremely low. Regarding stroke and cancer, stroke often has a sudden onset and causes severe and lasting disability, and both are the life-threatening diseases; therefore, these diagnoses have a significant impact on the patient in most cases. Further, the moderate agreement levels might be attributed to the increased awareness regarding these two diseases. Clinicians, nurses, and caregivers should make patients aware of their comorbidities, especially hypertension and COPD.

This is the first study to report a significant association between the accuracy of patient-reported comorbidities and patient prognosis in any patient population. The mechanism of this relationship is unclear; however, poor recognition of comorbidities may be associated with poor medication adherence. A retrospective study on 31,636 patients revealed poorer medication adherence in patients with more comorbidities. Healthcare providers should explain patients’ current medical conditions, including comorbidities, more adequately, especially to older patients with a history of heart failure, cognitive dysfunction, and a high number of comorbidities. As these patients are at high risk for the inaccurate recognition of their comorbidities, the patient’s family or proxies should also be involved in patient education. Moreover, pharmacist care and nurse practitioner education have been reported to improve knowledge of heart failure and clinical outcomes in patients with heart failure. The association between the accuracy of patient-reported comorbidities and patient prognosis may also be a result of the association between the number of comorbidities and prognosis. In this study, the results were consistent even after adjusting for several confounders. However, further studies are needed to fully determine the effects of these confounders.

In previous studies, the clinical effects of educational intervention on patients with heart failure have been examined. Due to the reportedly poor knowledge of medications among elderly patients, there may be room for intervention. One randomized controlled trial involving 223 patients with heart failure showed that educating patients regarding the cause of heart failure and rationale for heart failure medication by nurses reduced the incidences of death or rehospitalization. In another randomized controlled trial on 200 hospitalized patients with heart failure, comprehensive care including education on diet, medication, and self-monitoring was associated with lower risk of heart failure rehospitalization. However, this comprehensive care did not include education regarding the recognition of patients’ comorbidities. Based on the results of our study, we believe that education on patients’ comorbidities should be provided for patients with heart failure. However, as our opinion is not supported by substantial evidence, further studies are required to investigate the clinical efficacy of comprehensive care including education on patient’s comorbidities.

This study is not without limitations. First, although several studies have reported that educational level is associated with the accordance or discordance of comorbidities between patient reports and medical records, data regarding the patients’ educational levels were not available. Previous studies have shown that educational level is not associated with the accuracy of the recognition of comorbidities; however, this factor cannot be ruled out in this study. Second, the physician report was used as the gold standard in this study, though physicians may also misunderstand patients’ comorbidities. Third, even though

---

**Table 3** Cox hazards proportional analysis for all-cause mortality or heart failure rehospitalization

|                        | Unadjusted | Model 1 | Model 2 |
|------------------------|------------|---------|---------|
|                        | HR 95% CI  | P-value | HR 95% CI | P-value | HR 95% CI | P-value |
| High agreement group   | 1 (reference) |         | 1 (reference) |         | 1 (reference) |         |
| Fair agreement group   | 1.43 1.17–1.76 <0.001 |         | 1.28 1.03–1.58 0.026 |         | 1.25 1.01–1.56 0.041 |         |
| Low agreement group    | 2.60 1.38–4.89 0.003 |         | 2.81 1.44–5.48 0.002 |         | 2.74 1.40–5.35 0.003 |         |

CI, confidence interval; HR, hazard ratio.

*Model 1: adjusted for age, sex, body mass index, New York Heart Association class III or IV, current smoking status, systolic blood pressure, history of heart failure, hypertension, diabetes, atrial fibrillation, coronary artery disease, chronic obstructive pulmonary disease, estimated glomerular filtration rate, haemoglobin, albumin, sodium, left ventricular ejection fraction, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker prescription, beta-blocker prescription, mineralocorticoid receptor antagonist prescription, and log-transformed brain natriuretic peptide.

*Model 2: adjusted for the variables listed in Model 1, cognitive dysfunction, and the number of comorbidities.
Comorbidity knowledge and prognosis 1357

healthcare utilization has shown to improve the outcomes in patients with heart failure, we were unable to procure any data on healthcare utilization. Fourth, although we used the Mini-Cog test to evaluate cognitive dysfunction, its generalizability has been limited in patients with heart failure. Moreover, although we tried to evaluate cognitive dysfunction before discharge, hospitalized patients with acute heart failure may have temporary impaired cognitive function due to delirium or acute metabolic changes associated with heart failure, which might have impacted our study results. Fifth, objective assessment of the level of self-care in this study, such as the European Heart Failure Self-care Behavior Scale, was not evaluated. Moreover, whether the patients managed their medication by themselves or received help by their family/caregivers was not evaluated. Finally, this study included only Japanese patients; the generalizability of our findings may be limited.

In conclusion, patient-reported comorbidities were not accurate, and the poor recognition of comorbidities was associated with a poor prognosis in patients with heart failure.

Conflict of interest

Dr. Yuya Matsue and Takatoshi Kasai are affiliated with a department endowed by Philips Respironics, ResMed, Teijin Home Healthcare, and Fukuda Denshi, and Dr. Yuya Matsue received honorariums from Otsuka Pharmaceutical Co. and Novartis Japan. Dr. Kagiyama reports grants from Philips, Asahi KASEI Corporation, Toho Holdings Co. Ltd, and Inter Reha Co. Ltd outside of the submitted work. Dr. Kamiya has received research funding from Eiken Chemical Co. Ltd. The remaining authors have nothing to declare.

Funding

The FRAGILE-HF study was supported by Novartis Pharma Research Grants and a Japan Heart Foundation Research Grant. This work was also partially supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (grant number 18K15862).

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Kaplan–Meier curves for all-cause death or heart failure rehospitalization according to level of agreement Patients were divided into four groups based on the level of agreement, as follows: complete agreement (agreement score of 6), more under-reporting, more over-reporting, or an equal number of under- and over-reporting. The complete agreement group had a longer event-free survival than the groups with disagreement.

Table S1. Logistic regression analysis for agreement.

Table S2. Cox hazards proportional analysis for all-cause death or heart failure re-hospitalization according to level of agreement.

References

1. Hale MD, Santorelli G, Brundle C, Clegg A. A cross-sectional study assessing agreement between self-reported and general practice-recorded health conditions among community dwelling older adults. Age Ageing 2019; 49: 135–140.
2. Teh R, Doughty R, Connolly M, Broad J, Pillai A, Wilkinson T, Edlin R, Jatrama S, Dyali L, Kerse N. Agreement between self-reports and medical records of cardiovascular disease in octogenarians. J Clin Epidemiol 2013; 66: 1135–1143.
3. Ryden L, Sigstrom R, Nilsson J, Sundh V, Falk Erhag H, Kern S, Waern M, Ostling S, Wilkinson K, Skoog I. Agreement between self-reports, proxy-reports and the National Patient Register regarding diagnoses of cardiovascular disorders and diabetes mellitus in a population-based sample of 80-year-olds. Age Ageing 2019; 48: 513–518.
4. Sharma A, Zhao X, Hammill BG, Hernandez AF, Fornarow GC, Felker GM, Yancy CW, Heidenreich PA, EzekowitzJA, DeVo AD. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the Get With The Guidelines-Heart Failure Registry. Circ Heart Fail 2018; 11: e004646.
5. Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines-Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240–e327.
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Rutten LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.
7. Toback M, Clark N. Strategies to improve self-management in heart failure.
patients. Contemp Nurse 2017; 53: 105–120.

8. Huerta JM, Tormo MJ, Egea-Caparrós JM, Ortolá-Devesa JB, Navarro C. Accuracy of self-reported diabetes, hypertension and hyperlipidemia in the adult Spanish population. DINO study findings. Rev Esp Cardiol 2009; 62: 143–152.

9. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004; 57: 1096–1103.

10. Langballe R, John EM, Malone KE, Bernstein L, Knight JA, Lynch CF, Howell RM, Shore R, Woods M, Conannon P, Group WSC, Bernstein JL, Møllemkjaer L. Agreement between self-reported and register-based cardiovascular events among Danish breast cancer survivors. J Cancer Surviv 2018; 12: 95–100.

11. Ye F, Moon DH, Carpenter WR, Reeve B, United States. Green RL, Spearman K, Sheets NC, Pearlstein KA, Lucero AR, Wadde MR, Godley PA, Chen RC. Comparison of patient report and medical records of comorbidities: results from a population-based cohort of patients with prostate cancer. JAMA Oncol 2017; 3: 1035–1041.

12. Merzenich H, Blettner M, Niehoff D, Okura Y, Urban LH, Mahoney DW, Kasai T, Nagamatsu H, Ozawa T, Iwata K, Jujo K, Wada H, Ogasahara Y, Maekawa E, Konishi M, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Hamazaki N, Nozaki K, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Wakaume O, Oka K, Momomura SI, Kagiyama N, Matsue Y. Prevalence and prognostic value of the coexistence of anemia and frailty in older patients with heart failure. ESC Heart Fail 2021; 8: 625–633.

13. Merzenich H, Blettner M, Okura Y, Urban LH, Mahoney DW, Kasai T, Nagamatsu H, Ozawa T, Iwata K, Yamamoto S, Aizawa N, Makino A, Oka K, Momomura SI, Kagiyama N, Matsue Y. Prevalence and utility of the questionnaires-based FRAIL scale in older patients with heart failure: findings from the FRAGILE-HF study. J Am Med Dir Assoc 2021; 22: 1621–1626.

14. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681–694.

15. Barnard J, Rubin DB. Small-sample degrees of freedom with multiple imputation. Biometrika 1999; 86: 948–955.

16. Hoffmann J, Haastert B, Brune M, Kalteheuer M, Begun A, Chernyak N, Icks A. How do patients with diabetes report their comorbidities? Comparison with administrative data. Clin Epidemiol 2018; 10: 499–509.

17. Cannon JA, Molliett P, Perez-Moreno AC, Walters MR, Broomfield NM, McMurray JJV, Quinn TJ. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail 2017; 23: 464–475.

18. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefield M, Herbert R, Wu AW. Noncardiac comorbidities increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42: 1226–1233.

19. Fenech G, Vallee A, Cherian M, Kab S, Goldberg M, Zins M, Blacher J. Poor awareness of hypertension in France: the CONSTANCES population-based study. Am J Hypertens 2020; 33: 543–551.

20. Fag I, Gao P, Bao H, Tang X, Wang B, Feng Y, Cong S, Yuan J, Fan J, Lu K, Wang N, Hu T, Yang L. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med 2018; 6: 421–430.

21. Rolnick SJ, Pavloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res 2013; 11: 54–65.

22. Schumacher PM, Becker N, Tsuyuki RT, Griese-Mammen N, Koshman SL, McDonald MA, Bouvy M, Rutten FH, Laufs U, Bohn M, Schulz M. The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. ESC Heart Fail 2021; 8: 3566–3576.

23. Rice H, Say R, Bethavas V. The effect of nurse-led education on hospitalisation, readmission, quality of life and cost in adults with heart failure. A systematic review. Patient Educ Couns 2018; 101: 363–374.

24. Bosch-Lenders D, Maessen DW, Stoffers HE, Knotnerus JA, Winkens B, van den Akker M. Factors associated with appropriate knowledge of the indications for prescribed drugs among community-dwelling older patients with polypharmacy. Age Ageing 2016; 45: 402–408.

25. Custodis F, Rohlehr F, Wachter A, Mahaffey KK, Momomura SI, Kagiyama N, Matsue Y. Prevalence and utility of the questionnaires-based FRAIL scale in older patients with heart failure: findings from the FRAGILE-HF study. J Am Med Dir Assoc 2021; 22: 1621–1626.

26. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681–694.
chronic heart failure. Circulation 2005; 111: 179–185.

39. Kimmelstiel C, Levine D, Perry K, Patel AR, Sadanianzt A, Gorham N, Cunnie M, Duggan L, Cotter L, Shea-Albright P, Poppas A, LaBresh K, Forman D, Brill D, Rand W, Gregory D, Udelson JE, Lorell B, Konstam V, Furlong K, Konstam MA. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation 2004; 110: 1450–1455.

40. Li Y, Fu MR, Luo B, Li M, Zheng H, Fang J. The effectiveness of transitional care interventions on health care utilization in patients discharged from the hospital with heart failure: a systematic review and meta-analysis. J Am Med Dir Assoc 2021; 22: 621–629.